Aquagenic Pruritus in Myeloproliferative Neoplasms

University Hospital, Brest170 enrolled

Overview

Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms. Prospective work based on the distribution of a dedicated questionnaire.

Patients with myeloproliferative neoplasms identified and followed in French Hospitals. Patients could be followed for polycythemia vera or essential thrombocythemia or primary myelofibrosis. Distribution of the questionnaire to each patient with myeloproliferative neoplasm (treated or not) suffering from aquagenic pruritus. Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at the end.

Study Type

OBSERVATIONAL

Enrollment

170

Conditions

Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with one of three non-chromosomal Philadelphia-positive myeloproliferative neoplasms: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). * Suffering (or having suffered) from aquagenic pruritus. * No age limit, but major * Patient having formulated his non-opposition Exclusion Criteria: * Patients with MPN with non-aquagenic pruritus, * Patients with another hematologic disease and aquagenic pruritus * Patients unable to complete the questionnaire. * Patients with physical or mental disabilities to formulate non-opposition * Refusal of participation

Locations (11)

Lyon, Auvergne Rhônes-alpes, France

Quimper, Brestagne, France

Morlaix, Brittany Region, France

Saint-Brieuc, Brittany Region, France

Outcomes

Primary Outcomes

Description of pruritus in patients with myeloproliferative neoplasms

Intensity of pruritus (visual analogic scale)

Time frame: at the time of questionnaire completion (Day 0)

Secondary Outcomes

Description of therapies used to treat pruritus

Name of drugs used

Time frame: at the time of questionnaire completion (Day 0)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.